1 day ago
1
alexsl
Wall Street analysts have issued bullish views on Kymera Therapeutics (NASDAQ:KYMR) after the Watertown, Massachusetts-based biotech announced Phase 1 data for KT-621, its first-in-class oral anti-inflammatory agent.
Kymera (NASDAQ:KYMR) shares climbed ~46% on Monday after the company disclosed a well-tolerated safety
English (US) ·